
	<!DOCTYPE html>
	<html>
		<head>
			<title>【药明生物】中报业绩电话会要点总结</title>
			<meta charset="utf-8" />
		</head>
		<body>
			<div class="note-wrapper">
				<h1>【药明生物】中报业绩电话会要点总结</h1>
				<button class="btn btn-primary"><a href="../index.html">返回主页</a></button><br><br>
				【药明生物】中报业绩电话会要点总结<br><br>2022上半年是药明生物历史上最有挑战的一年，生物技术的发展减速，公司面临UVL挑战、上海封控，国内疫情此起彼伏，这种情况下公司依旧实现了去年良好基数上实现了靓丽增长。<br><br>1.上半年业绩增长迅猛，非新冠增速72.6%成为主要业绩动力：上半年收入增速63.%，非新冠增速72.6%，全年预计非新冠增速65%+，总收入和利润增速47%+；上半年新增综合项目59个，三期临床项目29个，商业化项目14个；合作两家跨国药企签订超过1亿美元生产合同，首次获得销售收入分成超2000万人民币；未完成订单总额增长至185亿美元，双抗、ADC、疫苗项目增长迅速。<br><br>2.“win-the-Molecule”战略拓宽研发管线加速收入增长：去年是公司CMO的拐点，CMO项目大幅度增长。一方面是因为公司跨国10年发展门槛，经过15次FDA和欧盟检查；另一方面新冠项目做的很完美，很多公司认可了药明生物CMO的能力；“win-the-Molecule”战略从大型药企获得更多长期商业化订单，目前10+临床三期项目正在积极洽谈中，CMO未来将共吸纳更大收入。<br><br>3.预计2026年后产能达58万升，积极拓展海外市场布局：预计公司2026年后产能达58万升，海外投资约30亿美元；搭建欧美全产业链平台支持业务增长，将重点建设新加坡一体化CRDMO中心，完善全球供应，北美、欧洲、中国及其他地区多重增长引擎推动可持续增长。<br><br>4. UVL取得重要进展，上半年积极应对疫情，影响可控：无锡工厂6月完成现场核查，8月美国已开始供应发货，上海工厂检查时间正在协商，全球客户合作如常；公司积极应对上海Q2疫情，业务受影响情况可控。<br><br>#文字纪要#
				<br><br><button class="btn btn-primary"><a href="../index.html">返回主页</a></button>
	
			</div>
			<script type="text/javascript">
				(function() {
	
		var doc_ols = document.getElementsByTagName("ol");
	
		for ( i=0; i<doc_ols.length; i++) {
	
			var ol_start = doc_ols[i].getAttribute("start") - 1;
			doc_ols[i].setAttribute("style", "counter-reset:ol_counter " + ol_start + ";");
	
		}
	
	})();
	
			</script>
			<style>
				html,body,div,span,applet,object,iframe,h1,h2,h3,h4,h5,h6,p,blockquote,pre,a,abbr,acronym,address,big,cite,code,del,dfn,em,img,ins,kbd,q,s,samp,small,strike,strong,sub,sup,tt,var,b,u,i,center,dl,dt,dd,ol,ul,li,fieldset,form,label,legend,table,caption,tbody,tfoot,thead,tr,th,td,article,aside,canvas,details,embed,figure,figcaption,footer,header,hgroup,menu,nav,output,ruby,section,summary,time,mark,audio,video{margin:0;padding:0;border:0;font:inherit;font-size:100%;vertical-align:baseline}html{line-height:1}ol,ul{list-style:none}table{border-collapse:collapse;border-spacing:0}caption,th,td{text-align:left;font-weight:normal;vertical-align:middle}q,blockquote{quotes:none}q:before,q:after,blockquote:before,blockquote:after{content:"";content:none}a img{border:none}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}*{-moz-box-sizing:border-box;-webkit-box-sizing:border-box;box-sizing:border-box}html{font-size:87.5%;line-height:1.57143em}html{font-size:14px;line-height:1.6em;-webkit-text-size-adjust:100%}body{background:#fcfcfc;color:#545454;text-rendering:optimizeLegibility;font-family:"AvenirNext-Regular"}a{color:#de4c4f;text-decoration:none}h1{font-family:"AvenirNext-Medium";color:#333;font-size:1.6em;line-height:1.3em;margin-bottom:.78571em}h2{font-family:"AvenirNext-Medium";color:#333;font-size:1.3em;line-height:1em;margin-bottom:.62857em}h3{font-family:"AvenirNext-Medium";color:#333;font-size:1.15em;line-height:1em;margin-bottom:.47143em}p{margin-bottom:1.57143em;hyphens:auto}hr{height:1px;border:0;background-color:#dedede;margin:-1px auto 1.57143em auto}ul,ol{margin-bottom:.31429em}ul ul,ul ol,ol ul,ol ol{margin-bottom:0px}ol{counter-reset:ol_counter}ol li:before{content:counter(ol_counter) ".";counter-increment:ol_counter;color:#e06e73;text-align:right;display:inline-block;min-width:1em;margin-right:0.5em}b,strong{font-family:"AvenirNext-Bold"}i,em{font-family:"AvenirNext-Italic"}code{font-family:"Menlo-Regular"}.text-overflow-ellipsis{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.sf_code_string,.sf_code_selector,.sf_code_attr-name,.sf_code_char,.sf_code_builtin,.sf_code_inserted{color:#D33905}.sf_code_comment,.sf_code_prolog,.sf_code_doctype,.sf_code_cdata{color:#838383}.sf_code_number,.sf_code_boolean{color:#0E73A2}.sf_code_keyword,.sf_code_atrule,.sf_code_rule,.sf_code_attr-value,.sf_code_function,.sf_code_class-name,.sf_code_class,.sf_code_regex,.sf_code_important,.sf_code_variable,.sf_code_interpolation{color:#0E73A2}.sf_code_property,.sf_code_tag,.sf_code_constant,.sf_code_symbol,.sf_code_deleted{color:#1B00CE}.sf_code_macro,.sf_code_entity,.sf_code_operator,.sf_code_url{color:#920448}.note-wrapper{max-width:46em;margin:0px auto;padding:1.57143em 3.14286em}.note-wrapper.spotlight-preview{overflow-x:hidden}u{text-decoration:none;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#e06e73 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}s{color:#878787}p{margin-bottom:0.1em}hr{margin-bottom:0.7em;margin-top:0.7em}ul li{text-indent:-0.35em}ul li:before{content:"•";color:#e06e73;display:inline-block;margin-right:0.3em}ul ul{margin-left:1.25714em}ol li{text-indent:-1.45em}ol ol{margin-left:1.25714em}blockquote{display:block;margin-left:-1em;padding-left:0.8em;border-left:0.2em solid #e06e73}.todo-list ul{margin-left:1.88571em}.todo-list li{text-indent:-1.75em}.todo-list li:before{content:"";display:static;margin-right:0px}.todo-checkbox{text-indent:-1.7em}.todo-checkbox svg{margin-right:0.3em;position:relative;top:0.2em}.todo-checkbox svg #check{display:none}.todo-checkbox.todo-checked #check{display:inline}.todo-checkbox.todo-checked+.todo-text{text-decoration:line-through;color:#878787}.code-inline{display:inline;background:white;border:solid 1px #dedede;padding:0.2em 0.5em;font-size:0.9em}.code-multiline{display:block;background:white;border:solid 1px #dedede;padding:0.7em 1em;font-size:0.9em;overflow-x:auto}.hashtag{display:inline-block;color:white;background:#b8bfc2;padding:0.0em 0.5em;border-radius:1em;text-indent:0}.hashtag a{color:#fff}.address a{color:#545454;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#0da35e 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}.address svg{position:relative;top:0.2em;display:inline-block;margin-right:0.2em}.color-preview{display:inline-block;width:1em;height:1em;border:solid 1px rgba(0,0,0,0.3);border-radius:50%;margin-right:0.1em;position:relative;top:0.2em;white-space:nowrap}.color-code{margin-right:0.2em;font-family:"Menlo-Regular";font-size:0.9em}.color-hash{opacity:0.4}.ordered-list-number{color:#e06e73;text-align:right;display:inline-block;min-width:1em}.arrow svg{position:relative;top:0.08em;display:inline-block;margin-right:0.15em;margin-left:0.15em}.arrow svg #rod{stroke:#545454}.arrow svg #point{fill:#545454}mark{color:inherit;display:inline;padding:0.2em 0.5em;background-color:#fcffc0}img{max-width:100%;height:auto}
			</style>
		</body>
	</html>
	